FGFR2 overexpression predicts survival outcome in patients with metastatic papillary renal cell carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

FGFR2 overexpression predicts survival outcome in patients with metastatic papillary renal cell carcinoma

Published:2016-07-05 Issue:2 Volume:19 Page:265-268
ISSN:1699-048X
Container-title:Clinical and Translational Oncology
language:en
Short-container-title:Clin Transl Oncol

Author:

Tsimafeyeu I.,Khasanova A.,Stepanova E.,Gordiev M.,Khochenkov D.,Naumova A.,Varlamov I.,Snegovoy A.,Demidov L.

Funder

Terry Fox Foundation

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12094-016-1524-y.pdf

Reference8 articles.

1. Tsimafeyeu I, Snegovoy A, Varlamov S, Safina S, Varlamov I, Gurina L, et al. Everolimus in patients with metastatic renal cell carcinoma previously treated with bevacizumab: a prospective multicenter study CRAD001LRU02T. Target Oncol. 2015;10:423–7.

2. Linehan WM, Bratslavsky G, Pinto PA, Schmidt LS, Neckers L, Bottaro DP, et al. Molecular diagnosis and therapy of kidney cancer. Annu Rev Med. 2010;61:329–43.

3. Rini BI, Atkins MB. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol. 2009;10:992–1000.

4. Saylor PJ, Escudier B, Michaelson MD. Importance of fibroblast growth factor receptor in neovascularization and tumor escape from antiangiogenic therapy. Clin Genitourin Cancer. 2012;10:77–83.

5. Tsimafeyeu I, Bratslavsky G. Fibroblast growth factor receptor 1 as a target for the therapy of renal cell carcinoma. Oncology. 2015;88:321–31.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Developing New Peptides and Peptide–Drug Conjugates for Targeting the FGFR2 Receptor-Expressing Tumor Cells and 3D Spheroids;Biomimetics;2024-08-27

2. Aberrations in FGFR1, FGFR2, and RIP5 Expression in Human Congenital Anomalies of the Kidney and Urinary Tract (CAKUT);International Journal of Molecular Sciences;2022-12-08

3. The Integrated Analyses of Driver Genes Identify Key Biomarkers in Thyroid Cancer;Technology in Cancer Research & Treatment;2020-01-01

4. Investigational fibroblast growth factor receptor 2 antagonists in early phase clinical trials to treat solid tumors;Expert Opinion on Investigational Drugs;2019-10-03

5. Comprehensive analysis of differentially expressed profiles and reconstruction of a competing endogenous RNA network in papillary renal cell carcinoma;Molecular Medicine Reports;2019-04-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3